Tolerability and antihypertensive efficacy of losartan vs captopril in patients with mild to moderate hypertension and impaired renal function. A randomised, double-blind, parallel study

Clinical Drug Investigation

Volumn 19, Issue 3, 2000, Pages 183-194

  Schulz, Egbert ^a   Bech, Jasper ^a   Pedersen, E B ^a   Zavala, Rodolfo ^a   Ruiz, Mauricio ^a   Müller, Gerhard Anton ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CAPTOPRIL; CHOLESTEROL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOSARTAN; TRIACYLGLYCEROL;

ABDOMINAL PAIN; ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; ASTHENIA; BORDERLINE HYPERTENSION; BRONCHITIS; CHILL; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CREATININE CLEARANCE; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; DYSPNEA; EDEMA; FATIGUE; HEART PALPITATION; HEMATOMA; HUMAN; INFLUENZA; KIDNEY FAILURE; LOWER RESPIRATORY TRACT INFECTION; LUNG EMBOLISM; LUNG INFARCTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NOSE CONGESTION; PARALLEL DESIGN; PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SYNCOPE; SYSTOLIC BLOOD PRESSURE; THORAX PAIN; UPPER RESPIRATORY TRACT INFECTION;

EID: 0034024818     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200019030-00003     Document Type: Article

References (41)

1. 1. Wolf G, Neilson EG. Angiotensin II as a renal growth factor. J Am Soc Nephrol 1993; 3: 1531-40
2. 2. Schulz E, Ruschitzka F, Lueders S, et al. Effects of endothelin on hemodynamics, prostaglandins, blood coagulation and renal function. Kidney Int 1995; 47: 795-801
3. 3. Ballermann BJ. Vasoactive peptides and the kidney. In: Brenner BM, Rector FC, editors. The kidney. Philadelphia: WB Saunders, 1991: 510-83
4. 4. Friberg P. The renin-angiotensin system in neonatal rats: Induction of renal abnormality in response to ACE inhibition or angiotensin II antagonism. Kidney Int 1994; 45: 485-92
5. 5. Mitchell KD, Braam B, Navar LG. Hypertensinogenic mechanisms mediated by renal actions of the renin-angiotensin system. Hypertension 1992; 19 Suppl. I: I-8-I-27
6. 6. Kost Jr CK, Jackson EK. Enhanced renal angiotensin II subtype 1 receptor responses in the spontaneously hypertensive rat. Hypertension 1993; 21 (4): 420-31
7. 7. Williams GH, Hollenberg NK. Non-modulating hypertension: a subset of sodium-sensitive hypertension. Hypertension 1991; 17 (1 Suppl. I): I-81-I-85
8. 8. Rosenberg ME. The paradox of the renin-angiotensin system in chronic renal disease. Kidney Int 1994; 45: 403-10
9. 9. Bottari SP. The angiotensin AT2 receptor stimulates protein tyrosine phosphatase activity and mediates inhibition of particulate guanylate eyelase. Biochem Biophys Res Commun 1992; 183: 206-11
10. 10. Kambayashi Y. Molecular cloning of a novel angiotensin receptor isoform involved in phosphotyrosine phosphatase inhibition. J Biol Chem 1993; 268: 24543-6
11. 11. Stoll M. The angiotensin AT2 receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest 1995; 95 (2): 651-7
12. 12. Timmermann PB, Carini DJ, Chiu AT. The discovery of a new class of highly specific nonpeptide angiotensin II receptor antagonists. Am J Hypertens 1991; 4 (4): 275S-281S
13. 13. Burnier M, Waeber M, Brunner HR. Clinical pharmacology of the angiotensin II receptor antagonist losartan potassium in healthy subjects. J Hypertens 1995; 13 Suppl. I: S23-S28
14. 14. Gradmann AH, Arcuri KE, Goldberg AI, et al. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension 1995; 25: 1345-50
15. 15. Soldner A, Spahn-Langguth H, Mutschler E. Disposition profiles of losartan and EXP3174 in rat tissues and body fluids following single and multiple oral dosing (abstract Nr. 790). 7th European Meeting on Hypertension, June 1995; Milan, Italy
16. 16. Lo MW, Goldberg MR, McCrea MG. Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin Pharmacol Ther 1995; 58: 641-9
17. 17. Sica DA, Lo MW, Shaw WC. The pharmacokinetics of losartan in renal insufficiency. J Hypertens 1995; 13 Suppl. I: S49-52
18. 18. Rodicio JL, Alcazar JM, Ruilope LM. Influence of converting enzyme inhibition on glomerular function and proteinuria. Kidney Int 1990; 38: 590-4
19. 19. The GISEN group. Randomized placebo-controlled trial of the effect of Ramipril on decline in glomerular filtration rate and risk of terminal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 349: 1857-63
20. 20. Gohlke P. Angiotensin-converting enzyme inhibition improves cardiac function: role of bradykinin. Hypertension 1994; 23: 411-8
21. 21. Mayer G, Lafayette RA, Oliver J, et al. The effects of angitensin II receptor blockade on remnant glomerular permselectivity. Kidney Int 1993; 43 (2): 346-53
22. 22. Remuzzi A, Perico N, Amuchastegui CS. Short and long term effect of angiotensin II receptor blockade in rats with experimental diabetes. J Am Soc Nephrol 1993; 4: 40-9
23. 23. Gansevoort RT, De Zeuw D, De Jong PE. Is the antiproteinuric effect of ACE inhibition mediated by interference with the renin-angiotensin system? Similar response to angiotensin II receptor antagonism and ACE inhibition. Kidney Int 1994; 45: 861-7
24. 24. Jover B, Mimran A. Angiotensin II receptor antagonists versus angiotensin-converting-enzyme inhibitors: effects on renal function. J Hypertens 1994; 12 Suppl. 9: S3-S9
25. 25. Praga L. Long-term beneficial effects of angiotensin-converting enzyme inhibition in patients with nephrotic proteinuria. Am J Kidney Dis 1992; 20 (3): 240-8
26. 26. Weber MA, Byyny RL, Pratt JH. Blood pressure effects of the angiotensin II receptor blocker losartan. Arch Intern Med 1995; 27 (155): 405-11
27. 27. Goldberg AI, Dunlay MC, Sweet CS, et al. Safely and tolerability of losartan potassium, an angiotensin II receptor antgonist, compared with hydrochlorothiazid, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. J Am J Cardiol 1995; 75: 793-5
28. 28. Lacouciere Y, Lefebvre J, Nakhle G, et al. Association between cough and angiotensin converting enzyme inhibitors and angiotensin II antagonists: the design of a prospective, controlled study. J Hypertens 1994; 12 Suppl. 2: S49-S53
29. 29. Packer M, Lee WH, Yushak M, et al. Comparison of captopril and enalapril in patients with severe chronic heart failure. N Engl J Med 1986; 315: 847-53
30. 30. Chan JCN, Critchley JAJH, Lappe JT, et al. A randomized, double-blind, parallel study of the antihypertensive efficacy and safety of losartan potassium compared with felodipine ER in elderly patients with mild to moderate hypertension. J Hum Hypertens 1995; 9: 765-71
31. 31. Dahlöf B, Keller SE, Makris L, et al. Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension. Am J Hypertens 1995; 8: 578-83
32. 32. Kasiske BL, Kalil RS, Ma JZ, et al. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta regression analysis. Ann Intern Med 1993; 118: 129-38
33. 33. Kamper AL, Strandgaard S, Leysaac PP. Effect of enalapril on the progression of chronic renal failure: a randomized controlled study. Am J Hypertens 1992; 5: 423-30
34. 34. Nelson E, Arcuri K, Ikeda L, et al. Efficacy and safety of losartan in patients with essential hypertension. Am J Hypertens 1992; 5: 19A-20A
35. 35. Gansevoort RT, de Zeeuw D, Shahinfar S, et al. Effects of the angiotensin II antagonist losrtan in hypertensive patients with renal disease. J Hypertens 1994; 12 Suppl. 2: S37-S42
36. 36. Maillon JM, Bradstreet DC, Makris L, et al. Antihypertensive efficacy and tolerability of once daily losartan potassium compared with captopril in patients with mild to moderate essential hypertension. J Hypertens 1995; 13 Suppl. 1: S35-S41
37. 37. Tikkanen I, Omvik P, Jensen HA for the Scandinavian study group. Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension. J Hypertens 1995; 13: 1343-51
38. 38. Pitt B, Segal R, Martinez FA, et al, on behalf of ELITE study investigators. Randomized trial of losartan versus captopril in patients over 65 with heart failure devaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349: 747-52
39. 39. Holdaas H, Hartmann A, Nordal K, et al. The albuminuric sparing effect of losartan is mediated by a renal hemodynamic effect and not by changes in tubular function or glomerular sieving. Meeting of the International Society of Nephrology June 1997; Sydney, Australia
40. 40. Nielsen S, Dollerup J, Nielsen B, et al. Losartan reduces albuminuria in patients with essential hypertension. An enalapril controlled 3 months study. Nephrol Dial Transplant 1997; 12 Suppl. 2: 19-23
41. 41. Strutz F, Müller GA. Renal fibrogenesis and progression. In: Nielsen EG, Couser WC, editors. Immunologic renal diseases. Philadelphia, New York: Lipincott-Raven, 1997: 705-26